IRIS - Res&Arch Institutional Research Information System - Research & Archive

PARNETTI, Lucilla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.004
EU - Europa 6.653
AS - Asia 2.626
AF - Africa 17
OC - Oceania 15
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 18.339
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.983
IE - Irlanda 1.737
UA - Ucraina 1.406
IT - Italia 1.113
SG - Singapore 900
SE - Svezia 704
HK - Hong Kong 700
VN - Vietnam 479
FI - Finlandia 388
DE - Germania 384
CN - Cina 350
RU - Federazione Russa 315
FR - Francia 147
GB - Regno Unito 118
RO - Romania 74
TR - Turchia 64
KR - Corea 63
CH - Svizzera 55
AT - Austria 39
NL - Olanda 35
BE - Belgio 34
CZ - Repubblica Ceca 34
UZ - Uzbekistan 22
GR - Grecia 21
PL - Polonia 21
EG - Egitto 17
CA - Canada 13
EU - Europa 11
LB - Libano 11
BR - Brasile 9
ES - Italia 9
JP - Giappone 9
NZ - Nuova Zelanda 9
IR - Iran 8
MX - Messico 7
AU - Australia 6
AM - Armenia 5
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
DK - Danimarca 3
TW - Taiwan 3
BG - Bulgaria 2
CL - Cile 2
CO - Colombia 2
LT - Lituania 2
NO - Norvegia 2
RS - Serbia 2
AZ - Azerbaigian 1
BD - Bangladesh 1
ID - Indonesia 1
IL - Israele 1
IN - India 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
PT - Portogallo 1
SA - Arabia Saudita 1
SV - El Salvador 1
Totale 18.339
Salva come PNG Salva come JPEG
Città #
Chandler 1.966
Dublin 1.736
San Mateo 850
Jacksonville 745
Hong Kong 694
Boardman 682
Singapore 656
Dong Ket 479
Altamura 474
Medford 405
Princeton 402
Wilmington 357
Lawrence 355
Perugia 291
Ann Arbor 259
Des Moines 247
Andover 184
Beijing 156
Saint Petersburg 121
Ashburn 114
San Paolo di Civitate 94
Falls Church 93
Helsinki 90
Los Angeles 78
Norwalk 73
Woodbridge 66
Seoul 60
Izmir 58
Redmond 54
Timisoara 35
Brussels 34
Bucharest 34
Rome 31
Munich 30
Dallas 29
Redwood City 27
New York 25
Houston 24
Moscow 22
Santa Clara 21
Shanghai 21
Den Haag 20
Lausanne 19
Auburn Hills 17
Fairfield 17
Frankfurt Am Main 14
Lappeenranta 14
Brno 13
Saint Louis 11
Giza 10
Paris 10
Amsterdam 9
Bologna 9
Milan 9
San Diego 9
Tappahannock 9
Chicago 8
Florence 8
Olomouc 8
Seattle 7
Ardabil 6
Auckland 6
Madrid 6
Monmouth Junction 6
Tokyo 6
Toronto 6
Fremont 5
Mcallen 5
Turin 5
Adelaide 4
Cava de' Tirreni 4
Guangzhou 4
Hanover 4
Istanbul 4
Naples 4
Ottawa 4
Philadelphia 4
Terni 4
Yerevan 4
Al Mansurah 3
Bratislava 3
Brescia 3
Cambridge 3
Clifton 3
Duino-Aurisina 3
Edinburgh 3
El Paso 3
Frankfurt am Main 3
Harbin 3
Kiev 3
Lissone 3
Palermo 3
Radeberg 3
San Juan 3
Saronno 3
Sesto Fiorentino 3
Vienna 3
Zhengzhou 3
Alviano 2
Aprilia 2
Totale 12.545
Salva come PNG Salva come JPEG
Nome #
Apopoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer’s disease and vascular dementia patients 118
CSF and blood biomarkers for Parkinson's disease 117
A new assay for antiphospholipid antibodies in patient with ischemic stroke 112
Platelet MAO-B activity and vitamin B12 in old age dementias. 102
Effect of acetyl-L-carnitine on serum levels of cortisol and adrenocorticotropic hormone and its clinical effect in patients with senile dementia of Alzheimer type 98
102.Evolutionary trends in carotid atherosclerotic plaques: results of a two-year follow-up study using an ultrasound imaging system. 95
First-ever stroke and outcome in patients admitted to Perugia Stroke Unit:predictors for death, dependency, and recurrence of stroke within the first three months. 94
a-D-Mannosidses in patients with familial Alzheimer's Disease 92
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients 92
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. 89
a-D-Mannosidases in patients with Alzheimer's disease 88
Brain SPECT in pathological aging brain: Alzheimer's disease, mild cognitive impairment and age-associated cognitive impairment. 87
Swalloving dysfunction: neurovascolar- anatomical correlation. 84
Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type 78
Acetylcholinesterase and butyrylcholinesterase activity in cerebrospinal fluid of Alzheimer patients before and after 6-months treatment with donepezil. XXXI Congresso Società Italiana di Neurologia 78
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease 77
Stroke related to carotid artery dissection in a young patient with Takayasu arteritis, systemic lupus erythematosus and antiphospholipid antibody syndrome. 76
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies 76
Variazioni di attività della paraoxonasi serica nella fase acuta dello stroke ischemico. Stroke'99 Meeting on Cerebrovascular Diseases 75
Risk factors and stroke subtypes: results of five consecutive years of the Perugia Stroke Registry 75
Cerebrospinal fluid biomarkers in Parkinson disease. 74
Neuroendocrine markers in aging brain: clinical and neurobiological significance of dexamethasone suppression test 73
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies 73
Brain SPECT in pathological aging brain: Alzheimer’s disease, mild cognitive impairment and age-associated cognitive impairment 72
Neuropsychological results of long-term therapy with oxiracetam in DAT/MID patients in comparison with a control group 72
Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia. 72
Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI) 72
Expression of d-mannosidase in amyotrophic lateral sclerosis and Alzheimer's disease 71
Vascular cognitive impairment: a pragmatic concept 71
Cerebrospinal fluid biomarkers and white matter lesions: can we know more? 71
Early admission to stroke unit influences clinical outcome 71
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. 71
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. 71
Blood pressure and functional aspects of the aging brain. 71
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 71
Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia. 70
The role of haemorheological factors in the ageing brain: long-term therapy with pentoxifylline ('Trental' 400) in elderly patients with initial mental deterioration. 70
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology 70
Brain SPECT in the diagnosis of degenerative dementia. 69
99mTc-HMPAO-SPECT nell'invecchiamento cerebrale fisiologico, nei deficit di memoria età correlati e nella malattia di Alzheimer: studio longitudinale a un anno. 69
Association between migraine and headache attributed to stroke: a case-control study. 69
1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. 69
Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis 69
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease 69
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis 69
Influence of dementia on antithrombotic therapy prescribed before stroke in patients with atrial fibrillation. 68
99mTc-HMPAO cerebral SPECT in cerebrovascular disease with and without dementia. 68
[Whole blood filterability in chronic cerebrovascular disorders: effects of the use of buflomedil hydrochloride]. 68
Hippocampal epileptogenesis in autoimmune encephalitis 68
Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome 68
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 67
Brain SPECT in pathological aging brain: Lewy Body Disease and Age-Associated Memory Impairment. 66
Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. 66
Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. 65
Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. 65
Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. 65
Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients. 65
B-mode imaging and histomorphometric evaluation of carotid atherosclerosis. 64
Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies 64
Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment. 63
Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. 63
Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. 63
Lysosomal enzymes in Parkinson's disease 63
Italian frontotemporal dementia network (FTD group-SINDEM): Sharing clinical and diagnostic procedures in Frontotemporal dementia in Italy 63
Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids 63
Repeatable Battery for the Assessment of Neuropsychological Status: Italian Normative Data for Older Adults 62
Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. 62
Acetyl-L-carnitine in the treatment of mildly demented elderly patients. 62
Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. 61
99mTc-HMPAO-SPECT contribution in the differential diagnosis of cognitive dysfunction. 61
Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience 61
Activation of complement and contact system in Alzheimer’s disease 61
Semi-quantitative analysis of perfusion of Brodmann areas in the differential diagnosis of cognitive impairment in Alzheimer's disease, fronto-temporal dementia and mild cognitive impairment. 61
Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link? 61
Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 61
White matter changes in stroke patients. Relationship with stroke subtype and outcome. 60
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. 60
Selection of thrombogenetic antiphospholipid antibodies in cerebrovascular disease patients. 60
Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia 60
Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. 60
[Drinking-water and cardiovascular mortality]. 59
Carotid atherosclerotic disease: role of hypertension and other risk factors. 59
The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction 59
A magnetization transfer study of mild and advanced Parkinson's disease. 59
Is multi-infarct dementia representative of vascular dementias? A retrospective study 58
Brain SPECT in different dementia disorders: AD, Possible AD, Preclinical AD, AAMI, FTD, LBD, VaD, secondary dementia. 58
Arterial hypertension and stroke prevention: an update. 58
Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type. 58
A combination of CSF Tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. 57
Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. 57
Are we ready for detecting α-synuclein prone to aggregation in patients? The case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as diagnostic tools 57
Le emozioni nei contesti individuali e sociali 57
Atrial fibrillation and stroke. 56
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies 56
Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimer’s Disease 56
Lysosomial hydrolase in cerebrospinal fluid from subjects with Parkinson's disease 55
Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. 55
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. 55
Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group. 55
Pathogenetic mechanisms in vascular dementia. 55
Totale 6.929
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.368
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.368
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.132 0 0 0 0 199 12 239 35 281 139 77 150
2020/20213.135 16 204 90 217 989 137 202 39 340 123 240 538
2021/20223.192 80 580 88 141 96 85 53 944 100 131 372 522
2022/20236.532 437 1.297 81 564 491 799 15 271 2.295 18 197 67
2023/20242.424 184 280 126 59 27 14 463 97 273 99 397 405
2024/20251.269 86 606 234 283 60 0 0 0 0 0 0 0
Totale 19.173